Keytruda results On another Merck subject, Keytruda will likely be approved soon for NMIBC. The advisory committee voted 9 to 4 last month to approve. Research notes say they expect to make 250 million a year initially from that indication. The holdup is "efficacy concerns".
They will collect our 250 million until we get approved or they buy us. I don't see them giving up that money because it would be much cheaper to buy us even though the price will be in the billions by then.